Lubiprostone

# Lubiprostone ## Overview - **Classification**: Chloride Channel Activator - **Mechanism**: Activates ClC-2 chloride channels in the GI tract, increasing intestinal fluid secretion and motility, softening stool, and promoting bowel movements. ## Primary Indications 1. **Chronic Idiopathic Constipation (CIC)** - Treatment of adults and pediatric patients 6 years and older. 2. **Irritable Bowel Syndrome with Constipation (IBS-C)** - Treatment of adults. 3. **Opioid-Induced Constipation (OIC)** - Treatment of adults with chronic non-cancer pain. ## Adult Dosing ### Standard Dosing **Chronic Idiopathic Constipation (CIC) & Opioid-Induced Constipation (OIC)** - **Dose**: **24 mcg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Special consideration**: Take with food and water. **Irritable Bowel Syndrome with Constipation (IBS-C)** - **Dose**: **8 mcg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Special consideration**: Take with food and water. ### Dose Adjustments - **Renal Impairment**: - Mild-Moderate: No adjustment needed. - Severe (CrCl < **30 mL/min**): - CIC/OIC: Initiate with **8 mcg** BID. - IBS-C: Initiate with **8 mcg** once daily. - **Hepatic Impairment**: - Moderate (Child-Pugh B): - CIC/OIC: Initiate with **16 mcg** BID. - IBS-C: Initiate with **8 mcg** once daily. - Severe (Child-Pugh C): - CIC/OIC: Initiate with **8 mcg** BID. - IBS-C: Initiate with **8 mcg** once daily. - **Elderly Patients**: No specific dose adjustment generally needed. ## Pediatric Dosing ### Neonates (0-28 days) - **Special Notes**: Not approved. Safety and efficacy not established. ### Infants (1-12 months) - **Special Notes**: Not approved. Safety and efficacy not established. ### Children (1-5 years) - **Special Notes**: Not approved. Safety and efficacy not established. ### Children (6-17 years) **Chronic Idiopathic Constipation (CIC)** - **Dose**: **24 mcg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Maximum**: **24 mcg** BID - **Special Notes**: Take with food and water to reduce nausea. Swallow capsules whole; do not crush or chew. ### Adolescents (13-18 years) **Chronic Idiopathic Constipation (CIC)** - **Dose**: **24 mcg** - **Frequency**: Twice daily (BID) - **Route**: Oral - **Maximum**: **24 mcg** BID - **Special Notes**: Dosing is same as for adults and children 6-17 years for CIC. ## Safety Information ### Contraindications - **Absolute**: Known or suspected mechanical gastrointestinal obstruction. - **Absolute**: Severe diarrhea. ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Abdominal pain, Abdominal distension, Flatulence, Headache. - **Common (1-10%)**: Vomiting, Dyspepsia, Peripheral edema, Dizziness, Fatigue, Dry mouth. - **Serious but Rare**: Dyspnea (transient), Syncope, Hypotension, Fainting. ### Key Drug Interactions - **Methadone**: May reduce lubiprostone's efficacy in some patients. - **Clinical significance**: Monitor for decreased therapeutic effect. - **Other laxatives**: Concomitant use may increase risk of diarrhea. - **Monitoring requirement**: Advise caution and monitor for excessive bowel movements. ## Monitoring & Follow-up - **Before Treatment**: Rule out mechanical bowel obstruction. - **During Treatment**: Monitor for resolution of constipation, frequency/consistency of bowel movements. - **During Treatment**: Monitor for adverse effects like nausea, diarrhea, abdominal pain. - **Clinical Signs**: Watch for signs of dehydration if diarrhea is severe or persistent. - **Clinical Signs**: Watch for transient dyspnea, typically occurring within an hour of the first dose. ## Clinical Pearls - 💡 **Tip 1**: Always take lubiprostone **with food and water** to significantly reduce the incidence and severity of nausea. - 💡 **Tip 2**: Capsules must be swallowed **whole**. Do not crush, chew, or break, as this may alter drug release. - 💡 **Tip 3**: May cause **transient dyspnea** shortly after the first dose; reassure patients this is usually self-limiting. - 💡 **Tip 4**: Not recommended for use in **pregnancy** (based on animal data showing fetal harm). - 💡 **Tip 5**: Onset of action for CIC is often within **24-48 hours** for initial spontaneous bowel movement. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.